Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
about
The Evolving Treatment Landscape for Metastatic Differentiated Thyroid CancerClinical management of regorafenib in the treatment of patients with advanced colorectal cancerAxitinib in Metastatic Renal Cell CarcinomaOverview and management of dermatologic events associated with targeted therapies for medullary thyroid cancerSunitinib in the treatment of metastatic renal cell carcinomaMultikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for OncologyDevelopment and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K).Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3)Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study.Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.Anti-VEGF therapy in breast and lung mouse models of cancers.A phase I study of sunitinib plus capecitabine in patients with advanced solid tumorsConcurrent hand-foot skin reaction and hair depigmentation with sunitinib: report of a case and literature review of kinase inhibitors and blocking antibodiesEfficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving CapecitabineHand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer: a case report.Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.Sorafenib induces delayed-onset cutaneous hypersensitivity: a case seriesQuantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implicationsRegorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyEffectiveness of medical supportive team for outpatients treated with sorafenib: a retrospective studyHand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: A case report and review of the literatureMultikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma.Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot studyTargeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical studyClinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosisSorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
P2860
Q26795503-F5DF3A73-BAFF-440A-BEA8-50AE5399804DQ26821956-A73E6E53-0955-48A4-B436-DB0753CC3D60Q26998017-5F8C1BC7-BAB4-4760-8CD6-A9B6D65CE516Q27005701-220134E8-AAFB-4A8A-B47B-440D54C55D11Q28072057-4BAEF685-6E68-4167-A5BB-058A2EA74291Q30250106-4E7F1548-C158-4FE2-9482-118D9079FEDFQ30279166-8D24194E-344A-4ADC-9CCA-BD59151EC7D2Q30355066-48875944-954B-4E5A-9482-2A6A277C0C9EQ33514852-9E6E1626-934F-40F4-9BB0-0E3BBC386CDEQ33699635-0854B125-9AD3-46DE-93ED-D99E41010C82Q33728605-4D8B8373-F02E-403C-A1E0-58DD9401BDBDQ33885559-AB756792-06AD-4FEE-9007-C1E08B1AE36DQ33889920-66D79422-92E6-44E9-80C9-F9ECAAEFEEECQ34042709-6F98414D-77AE-450A-A16B-CE2DD9AA5B89Q34141660-62FF1629-584C-4B75-B0CD-ACD070B7A465Q34197835-6081280A-70C3-4D3D-B915-CB0E0E731BC8Q34207858-39CB2A16-52A1-486B-AC8B-10EC25D62BBFQ34284723-12AAE93A-9BBF-4EF1-8C87-4767CC024CD8Q34334959-B6218486-58A2-4893-955D-7B78B6023D1DQ34591507-97F9070C-266C-4A36-82E0-FF8B913BC5EAQ34791173-E0FC985B-E681-4927-AFAF-6F7AC7E62750Q35123709-E821D545-4EA2-4DCC-8D5A-9C7510CB697DQ35172210-68F19A43-E6BE-4B49-B7A7-80D328F66150Q35420698-60EBBE63-B7C8-4E92-A335-C14D4789B1A1Q35450340-389FF54F-B7E1-4CAB-A534-9D19BF31A986Q35553882-A643CBCA-EBB9-485C-8672-CBD9D0AF7FFCQ35584405-044F812F-4A68-44DC-AB21-C7AF2A043106Q35599769-AFDBA175-8045-4BAF-A010-341A12413B75Q35759606-0E172587-0B8A-4590-BCD4-550A964F2363Q36078348-6CEB1D30-C6D6-45FE-BF28-4453FC0CEB9CQ36318627-5F3E529E-3475-4123-94E2-75609C87D50CQ36368199-7BF396CD-7ED3-40E7-B9D3-A588630C6144Q36424270-D7F4DBA3-737B-443B-8334-7B66AC46AC9CQ36463168-0F2BBFB7-82CA-4082-AE59-044CE0198ADDQ36500323-0403EEF0-E69F-4AA8-B730-2700F6CDC539Q37152133-49026169-66F0-43EC-9F1F-F187CFB06834Q37153412-19BA2418-6D82-47F6-9C63-B3FC00BB7E43Q37283736-F6CBE8C7-75D5-4435-941F-D24CD8F86C83Q37359379-5F9725EE-9B81-4C25-8404-4D86100A0E82Q37441574-198D1A85-249E-403C-9CFF-A00FF011AF72
P2860
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evolving strategies for the ma ...... itors sorafenib and sunitinib.
@en
Evolving strategies for the ma ...... itors sorafenib and sunitinib.
@nl
type
label
Evolving strategies for the ma ...... itors sorafenib and sunitinib.
@en
Evolving strategies for the ma ...... itors sorafenib and sunitinib.
@nl
prefLabel
Evolving strategies for the ma ...... itors sorafenib and sunitinib.
@en
Evolving strategies for the ma ...... itors sorafenib and sunitinib.
@nl
P2093
P50
P1433
P1476
Evolving strategies for the ma ...... bitors sorafenib and sunitinib
@en
P2093
Axel Hauschild
Caroline Robert
Doru T Alexandrescu
Janice P Dutcher
Joan Guitart
Laura Wood
Michael B Atkins
Roger T Anderson
Shenhong Wu
P304
P356
10.1634/THEONCOLOGIST.2008-0131
P577
2008-09-08T00:00:00Z